Expansion and Innovation to
Meet Growing Customer Demand
A Major Investment in Bloomington, Indiana
In response to increasing customer needs for development services and clinical and commercial manufacturing capacity, Simtra BioPharma Solutions is carrying out a $250 million expansion of its primary Bloomington sterile manufacturing campus and adding a new campus nearby. This expansion is the latest in a series of strategic, long-term investments in both facilities and capabilities to ensure that Simtra can satisfy growing customer demand for injectable manufacturing support, particularly for GLP-1 drugs and oncology product candidates.
Besides enabling Simtra’s customers to deliver more doses of life-sustaining therapies to patients, the expansion is expected to create hundreds of new jobs in Bloomington.
New Building, Additional Production Lines at Existing Campus
The expansion of the existing campus includes a 153,000-square-foot state-of-the-art building with 28,000 square feet of classified production area. It will house two high-speed, automated isolator syringe filling lines, one slated to be GMP-ready by mid-2026 and the other, by later in the year. Additionally a new high-speed isolator vial filling line is also expected to be GMP-ready by late 2027.
New Campus to Accommodate Multiple Manufacturing Suites
With its acquisition of a 65-acre property near the existing campus, Simtra is establishing its first U.S.-based commercial-scale capacity for injectable oncology drugs. By mid-2027, the new 300,000-square-foot building will contain a GMP-ready high-speed isolator vial line with three lyophilizers for high-potency drugs, including antibody-drug conjugates. In the near future, it will also house multiple client-dedicated production lines.